Investigation of the association between therapeutic effectiveness of anamorelin and Glasgow prognostic score in patients with cancer cachexia: a competing risk analysis
Investigational New Drugs · 2025
DOI: 10.1007/s10637-024-01503-6 ↗Kurz gefasst
Fachartikel in der Zeitschrift Investigational New Drugs, 2025. Verfasst von Kazuhiro Shimomura und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Aichi Cancer Center Hospital, 1-1, Kanokoden, Chikusa-Ku, Nagoya, Aichi, 464-8681, Japan. kazshimomura@aichi-cc.jp. Hauptthemen laut MEDLINE: Cachexia, Neoplasms, Oligopeptides, Hydrazines. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 32 Literaturangaben.
Abstract (Originalsprache)
Anamorelin, a highly selective ghrelin receptor agonist, enhances appetite and increases lean body mass in patients with cancer cachexia. However, the predictors of its therapeutic effectiveness are uncertain. This study aimed to investigate the association between the Glasgow prognostic score (GPS), used for classifying the severity of cancer cachexia, the therapeutic effectiveness of anamorelin, and the feasibility of early treatment based on cancer types. A retrospective analysis included patients with gastric, pancreatic, colorectal, and non-small-cell lung cancer treated with anamorelin between May 2021 and July 2022. The endpoints were the response rate for increased appetite within 3 weeks of treatment initiation and the time to treatment failure (TTF) due to therapeutic failure of anamorelin. Multivariate logistic regression model and Fine and Gray's model were used for analysis. Of the 137 patients in this analysis, 51% of patients had a GPS of 0 or 1, and 49% of those had a GPS of 2. Patients with a GPS of 2 showed a lower response for increased appetite than those with a GPS of 0 or 1 (adjusted odds ratio 0.29 [95% CI 0.12-0.72], P = 0.007). Additionally, TTF was shorter in patients with a GPS of 2 with a GPS of 0 or 1 (adjusted subdistribution hazard ratio 2.22 [95% CI 1.22-4.03], P = 0.009). Anamorelin could be more effective in improving appetite and prolonging the duration of treatment effect in patients with a GPS of 0 or 1 than those with a GPS of 2.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Aichi Cancer Center Hospital, 1-1, Kanokoden, Chikusa-Ku, Nagoya, Aichi, 464-8681, Japan. kazshimomura@aichi-cc.jp.
- Biostatistics Center, Kurume University, Kurume, Japan. kazshimomura@aichi-cc.jp.
- Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan.
- Department of Medical Oncology, Osaka International Cancer Institute, Osaka, Japan.
- Department of Pharmacy, Aichi Cancer Center Hospital, 1-1, Kanokoden, Chikusa-Ku, Nagoya, Aichi, 464-8681, Japan.
- Biostatistics Center, Kurume University, Kurume, Japan.
ORCID-Profile: Kazuhiro Shimomura
Zitieren
APA
Shimomura, K., Ogata, T., Maeda, A., Narita, Y., Taniguchi, H., Murotani, K., Fujiwara, Y., Tajika, M., Hara, K., Muro, K., & Uchida, K. (2025). Investigation of the association between therapeutic effectiveness of anamorelin and Glasgow prognostic score in patients with cancer cachexia: a competing risk analysis. Investigational New Drugs. https://doi.org/10.1007/s10637-024-01503-6
Vancouver
Shimomura K, Ogata T, Maeda A, Narita Y, Taniguchi H, Murotani K, et al. Investigation of the association between therapeutic effectiveness of anamorelin and Glasgow prognostic score in patients with cancer cachexia: a competing risk analysis. Investigational New Drugs. 2025. doi:10.1007/s10637-024-01503-6
BibTeX
@article{Shimomura2025,
author = {Shimomura, Kazuhiro and Ogata, Takatsugu and Maeda, Akimitsu and Narita, Yukiya and Taniguchi, Hiroya and Murotani, Kenta and Fujiwara, Yutaka and Tajika, Masahiro and Hara, Kazuo and Muro, Kei and Uchida, Kosaku},
title = {Investigation of the association between therapeutic effectiveness of anamorelin and Glasgow prognostic score in patients with cancer cachexia: a competing risk analysis},
journal = {Investigational New Drugs},
year = {2025},
doi = {10.1007/s10637-024-01503-6}
}
EUVIMED